Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

ABSTRACT: The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: * Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and * Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.

DISEASE(S): Metastatic Colorectal Cancer,Neoplasm Metastasis,The Aim Of This Study Is To Investigate The Following Schedules For Efficacy With Regard To Response Rate In Neoadjuvant Treatment Of Patients With Non-resectable Liver Metastases:- cetuximab/fol...,Colorectal Cancer,The Aim Of This Study Is To Investigate The Following Schedules For Efficacy With Regard To Response Rate In Neoadjuvant Treatment Of Patients With Non-resectable Liver Metastases: - cetuximab/folfoxiri And Cetuximab/folfiri In Patients With Ras Wild Type Tumours And - bevacizumab/folfoxiri And Folfoxiri In Patients With Ras Mutant Tumours.,Metastases To Liver

PROVIDER: 2140914 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR